BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System

    NEXT STORY
    NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial
    PREV STORY
    Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

    author_avatar
    NASDAQ Market News

    Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

    author_avatar
    NASDAQ Market News

    Oligonucleotide Synthesis Market Worth $3.9 Billion by 2025, Growing at a CAGR of 10.4% from 2019- Global Opportunity Analysis and Industry Forecasts by Meticulous Research®

    author_avatar
    NASDAQ Market News